AQR Capital Management
INMB icon

AQR Capital Management’s INmune Bio INMB Stock Holding History

AQR Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
662,218
+391,901
+145% +$542K ﹤0.01% 2963
2026
Q1 		$305K Buy
270,317
+249,798
+1,217% +$356K ﹤0.01% 3396
2025
Q4 		$32K Buy
20,519
+213
+1% +$380 ﹤0.01% 3532
2025
Q3 		$42K Buy
+20,306
New +$46.5K ﹤0.01% 3428

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

AQR Capital Management's INMB Position: Q2 2026 in Review

AQR Capital Management increased its INmune Bio (INMB) stake by 145% in Q2 2026, buying an estimated $542K and bringing the position to 662,218 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

AQR Capital Management first reported a position in INMB in Q3 2025 and has held it in 4 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • AQR Capital Management held 662,218 shares of INmune Bio worth $1.08M as of Q2 2026.
  • AQR Capital Management bought 391,901 INmune Bio shares in Q2 2026, an estimated $542K.
  • INmune Bio made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2963 holding.
  • AQR Capital Management first reported a position in INmune Bio in Q3 2025 and has held it in 4 quarters since.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.